Trader Edge / parameter - TLDR Gilead Sciences is acquiring Arcellx for $7.8 billion, paying $115 per share in cash plus a $5 contingent value right Arcellx stock jumped over 78% in premarket trading Monday following the announcement The deal centers on anito-cel, a CAR-T cell the…
Back to Top / Monday, February 23, 2026, 9:21 am / permalink 19567 / 3 stories in 11 days
Lilly’s obesity pill data stirs conflicting market reactions / 6 months
Anne Wojcicki reclaims 23andMe with a surprise multi‐million dollar buyback / 8 months
Eli Lilly to acquire Orna Therapeutics in a $2.4B biotech deal / 25 days
Novartis Acquires Avidity Biosciences for $12 Billion Expansion / 4 months
Amgen acquires Oxford’s Dark Blue Therapeutics in major biotech deal / 1 month
Kraft Heinz to Split Into Two Public Companies / 6 months
Keurig Dr Pepper moves forward with $18B acquisition of JDE Peet’s / 6 months
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.